Precigen, Inc. (PGEN)
| Market Cap | 1.42B |
| Revenue (ttm) | 9.68M |
| Net Income (ttm) | -429.64M |
| Shares Out | 353.93M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,419,378 |
| Open | 3.960 |
| Previous Close | 3.960 |
| Day's Range | 3.930 - 4.100 |
| 52-Week Range | 1.225 - 5.465 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 8.33 (+107.21%) |
| Earnings Date | May 13, 2026 |
About PGEN
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro... [Read more]
Financial Performance
In 2025, Precigen's revenue was $9.68 million, an increase of 146.73% compared to the previous year's $3.93 million. Losses were -$429.64 million, 240.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price target is $8.33, which is an increase of 107.21% from the latest price.
News
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a ...
Precigen Transcript: Fireside chat
PAPZIMEOS, the first immunotherapy for adult RRP, is driving a commercial transformation, with strong launch metrics, broad physician support, and robust payer access. The company is expanding its pipeline with pediatric trials, redosing studies, and new cancer indications leveraging its differentiated platform.
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (NASDAQ: PGEN) reported mixed results for the fourth quarter on Wednesday.
Precigen Earnings Call Transcript: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 revenue expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, while European expansion and pediatric trials are underway.
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZI...
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Independent, expert-led consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, reflects the recommendation of 16 leading physicians in the field of RRP Consensus paper reco...
Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference
A proprietary adenovirus platform enabled rapid development and full FDA approval of Pepcimeus for RRP, shifting care from surgery to a medical standard. Commercial launch saw swift market penetration, strong payer coverage, and broad physician adoption, with ex-U.S. expansion and cash flow positivity targeted by year-end.
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP PAPZIMEOS commercialization is well ...
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President ...
Precigen Earnings Call Transcript: Q3 2025
PAPZIMEOS secured full FDA approval and launched as the first therapy for adult RRP, showing strong efficacy, safety, and rapid commercial uptake. Q3 ended with $123.6M in cash, and breakeven is targeted by end of 2026, supported by robust demand and payer coverage.
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US as the first and only FDA-approved treatment for adults with RRP PAPZ...
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pati...
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed...
Precigen Announces Up to $125 Million Non-Dilutive Financing
$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and o...
Precigen Transcript: Fireside Chat
PAPZIMEOS, a first-in-class therapy for recurrent respiratory papillomatosis, received early FDA approval and is set for a broad U.S. launch. The company is expanding indications, has a strong financial runway, and is transitioning to a commercial biopharma model.
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pat...
Precigen Transcript: Investor Update
Papzimeos received full FDA approval as the first and only therapy for adult RRP, with a broad label and strong efficacy. The launch targets over 90% of the patient population, supported by robust infrastructure, financial assistance, and close collaboration with advocacy groups.
Why Is Precigen Stock Surging On Friday?
On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).
US FDA approves Precigen's immunotherapy for rare respiratory disease
The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul...
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD...
Precigen Reports First Quarter 2025 Financial Results and Business Updates
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targe...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
– International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, ...
Precigen Earnings Call Transcript: Q4 2024
PRGN-2012 advanced rapidly to FDA priority review, with pivotal data showing 51% durable complete response in RRP. Financially, a $126.2M net loss was offset by new funding, supporting operations into 2026 as commercialization preparations accelerate.